| Management of patients with Crohn’s disease and ulcerative colitis during the coronavirus disease-2019 pandemic: results of an international meeting DT Rubin, MT Abreu, V Rai, CA Siegel, V Ahuja, M Allez, ... Gastroenterology 159 (1), 6-13. e6, 2020 | 235 | 2020 |
| Histologic normalization occurs in ulcerative colitis and is associated with improved clinical outcomes B Christensen, SB Hanauer, J Erlich, O Kassim, PR Gibson, JR Turner, ... Clinical Gastroenterology and Hepatology 15 (10), 1557-1564. e1, 2017 | 208 | 2017 |
| Expert consensus on optimal acquisition and development of the International Bowel Ultrasound Segmental Activity Score [IBUS-SAS]: a reliability and inter-rater variability … KL Novak, K Nylund, C Maaser, F Petersen, T Kucharzik, C Lu, M Allocca, ... Journal of Crohn's and Colitis 15 (4), 609-616, 2021 | 157 | 2021 |
| prevention, diagnosis and management of COVID‐19 in the IBD patient AH Al‐Ani, RE Prentice, CA Rentsch, D Johnson, Z Ardalan, N Heerasing, ... Alimentary Pharmacology & Therapeutics 52 (1), 54-72, 2020 | 120 | 2020 |
| Safety and efficacy of combination treatment with calcineurin inhibitors and vedolizumab in patients with refractory inflammatory bowel disease B Christensen, PR Gibson, D Micic, RJ Colman, SR Goeppinger, ... Clinical Gastroenterology and Hepatology 17 (3), 486-493, 2019 | 97 | 2019 |
| Defining transabdominal intestinal ultrasound treatment response and remission in inflammatory bowel disease: systematic review and expert consensus statement JFKF Ilvemark, T Hansen, TM Goodsall, JB Seidelin, H Al-Farhan, ... Journal of Crohn's and Colitis 16 (4), 554-580, 2022 | 96 | 2022 |
| Histologic healing is more strongly associated with clinical outcomes in ileal Crohn’s disease than endoscopic healing B Christensen, J Erlich, PR Gibson, JR Turner, J Hart, DT Rubin Clinical Gastroenterology and Hepatology 18 (11), 2518-2525. e1, 2020 | 90 | 2020 |
| Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the … B Christensen, D Micic, PR Gibson, A Yarur, E Bellaguarda, P Corsello, ... Alimentary pharmacology & therapeutics 47 (6), 753-762, 2018 | 88 | 2018 |
| Vedolizumab as induction and maintenance for inflammatory bowel disease: 12-month effectiveness and safety B Christensen, RJ Colman, D Micic, PR Gibson, SR Goeppinger, A Yarur, ... Inflammatory bowel diseases 24 (4), 849-860, 2018 | 60 | 2018 |
| Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn’s disease TM Goodsall, V Jairath, BG Feagan, CE Parker, TM Nguyen, L Guizzetti, ... Alimentary pharmacology & therapeutics 53 (8), 873-886, 2021 | 56 | 2021 |
| Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid‐refractory ulcerative colitis JE Ollech, S Dwadasi, V Rai, N Peleg, I Normatov, A Israel, ... Alimentary Pharmacology & Therapeutics 51 (6), 637-643, 2020 | 55 | 2020 |
| Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure E Flanagan, PR Gibson, EK Wright, GT Moore, MP Sparrow, W Connell, ... Alimentary Pharmacology & Therapeutics 52 (10), 1551-1562, 2020 | 51 | 2020 |
| Understanding endoscopic disease activity in IBD: how to incorporate it into practice B Christensen, DT Rubin Current gastroenterology reports 18, 1-11, 2016 | 51 | 2016 |
| Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial JD Schulberg, EK Wright, BA Holt, AL Hamilton, TR Sutherland, AL Ross, ... The lancet Gastroenterology & hepatology 7 (4), 318-331, 2022 | 50 | 2022 |
| latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression—risks, screening, diagnosis and management SR Fehily, AH Al‐Ani, J Abdelmalak, C Rentch, E Zhang, JT Denholm, ... Alimentary Pharmacology & Therapeutics 56 (1), 6-27, 2022 | 46 | 2022 |
| low population mortality from COVID‐19 in countries south of latitude 35 degrees North—supports vitamin D as a factor determining severity. Authors' reply M Garg, A Al‐Ani, H Mitchell, P Hendy, B Christensen Alimentary pharmacology & therapeutics 51 (12), 1438, 2020 | 42 | 2020 |
| Toward transmural healing: Sonographic healing is associated with improved long‐term outcomes in patients with Crohn’s disease R Vaughan, D Tjandra, A Patwardhan, N Mingos, R Gibson, ... Alimentary Pharmacology & Therapeutics 56 (1), 84-94, 2022 | 41 | 2022 |
| Sustained virological response halts fibrosis progression: A long-term follow-up study of people with chronic hepatitis C infection SLG Chen Yi Mei, AJ Thompson, B Christensen, G Cunningham, ... PLoS One 12 (10), e0185609, 2017 | 32 | 2017 |
| Gastrointestinal ACE2, COVID-19 and IBD: Opportunity in the Face of Tragedy? M Garg, B Christensen, JS Lubel Gastroenterology 159 (4), 1623-1624. e3, 2020 | 26 | 2020 |
| Guidance for restarting inflammatory bowel disease therapy in patients who withheld immunosuppressant medications during COVID-19 CA Siegel, B Christensen, A Kornbluth, JR Rosh, MD Kappelman, ... Journal of Crohn's and Colitis 14 (Supplement_3), S769-S773, 2020 | 25 | 2020 |
